发明名称 |
BIOLOGICAL MARKERS USEFUL IN CANCER IMMUNOTHERAPY |
摘要 |
Methods are disclosed that are based on the finding that serum and plasma levels of eotaxin, MIP1a, and CRP act as important biomarkers that are useful for determining the feasibility in instigating immunotherapeutic treatment of cancer when immunizing with the GV1001 peptide (EARPALLTSRLRFIPK; derived from human telomerase protein), optionally when combined with state of the art combination treatment with Gemcitabine and Capecitabine. In particular, the present invention provides methods for determining whether patients should be treated GV1001 and for determining whether instigated treatment should be continued. |
申请公布号 |
PH12015502613(A1) |
申请公布日期 |
2016.02.29 |
申请号 |
PH2013120155026 |
申请日期 |
2015.11.23 |
申请人 |
GEMVAX AND KAEL CO., LTD.;KIM, SANG JAE |
发明人 |
KIM, SANG JAE |
分类号 |
G01N33/563;G01N33/574;G01N33/68 |
主分类号 |
G01N33/563 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|